This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds
by Zacks Equity Research
Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).
Tandem Diabetes Care Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Tandem Diabetes Care has been struggling lately, but the selling pressure may be coming to an end soon.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ
by Zacks Equity Research
Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.
Will Tandem Diabetes Care Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Tandem Diabetes Care.
Zacks.com featured highlights include: Crocs, Skechers, Tandem, CyberArk and Fortinet
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, Skechers, Tandem, CyberArk and Fortinet
Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
by Zacks Equity Research
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
Beyond Earnings Growth: Focus on Beat With These 5 Stocks
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next release.
Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
5 Top-Ranked Stocks Primed for an Earnings Beat
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
5 Top Picks on Three Key Takeaways From Q2 U.S. GDP
by Nalak Das
A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.
Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?
by Zacks Equity Research
In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.
Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Releases Positive Results Of t:slim X2 Pump Studies
by Zacks Equity Research
The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.
Why Is Tandem Diabetes (TNDM) Up 9.7% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Tandem (TNDM) Stock for Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.
Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.
Will Tandem Diabetes (TNDM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Tandem Diabetes (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?
by Zacks Equity Research
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Tandem Diabetes (TNDM) closed at $62.37 in the latest trading session, marking a +0.68% move from the prior day.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FYC
Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tandem Diabetes (TNDM) closed at $63.76, marking a +1.21% move from the previous day.